Literature DB >> 15883179

Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.

Cristina Gil-Lamaignere1, Regina Hess, Stefanie Salvenmoser, Kathrin Heyn, Reinhard Kappe, Frank-Michael C Müller.   

Abstract

OBJECTIVES: The effect of different media and composition on the in vitro activity of posaconazole, caspofungin and voriconazole against 59 zygomycetes species was determined.
METHODS: The media tested were RPMI 1640 medium with and without 2% glucose, antibiotic medium 3 (AM3) with and without 2% glucose, and high resolution (HR) medium.
RESULTS: Posaconazole was significantly more active than caspofungin and voriconazole, both in RPMI 1640 medium with 2% glucose and in HR medium. Adding glucose improved the determination of end points, but had only minor influence on the MICs. MICs evaluated in AM3 were lower than in RPMI 1640 medium or HR medium.
CONCLUSIONS: The in vivo effect of posaconazole in zygomycosis needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15883179     DOI: 10.1093/jac/dki140

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

6.  Posaconazole (Noxafil): a new triazole antifungal agent.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-04

Review 7.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 8.  Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.

Authors:  M Sandherr; G Maschmeyer
Journal:  Eur J Med Res       Date:  2011-04-28       Impact factor: 2.175

9.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.